562074-59-3

Usage

Uses

Used in Pharmaceutical Industry:
5-(CHLOROMETHYL)NICOTINONITRILE is used as an intermediate for the synthesis of antihypertensive drugs and other pharmaceuticals. Its ability to undergo various chemical reactions makes it a valuable building block in the development of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-(CHLOROMETHYL)NICOTINONITRILE is utilized in the synthesis of various biologically active compounds. Its versatility allows for the creation of new agrochemicals that can address various agricultural needs.
It is important to handle 5-(CHLOROMETHYL)NICOTINONITRILE with care, as it may be harmful if inhaled, ingested, or absorbed through the skin. Proper safety measures should be taken during its use in both pharmaceutical and agrochemical applications to ensure the well-being of those involved in its synthesis and production.

Upstream product

• 135124-71-9 5-(hydroxymethyl)pyridine-3-carbonitrile 
• 70416-53-4 5-formylpyridine-3-carbonitrile 
• 100949-02-8 5-vinylnicotinonitrile 
• 35590-37-5 5-bromopyridine-3-carbonitrile 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 37669-64-0 (5-bromopyridin-3-yl)methanol 

Relevant academic research and scientific papers

SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME

The present invention includes substituted 1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.

Biphenyl compound as immunoregulator and applications of same

The invention relates to a biphenyl compound as the formula (I), and a preparation method and a pharmaceutical application thereof. The groups in the formula (I) are defined as the specification. Thecompound can block the interaction between PD-1/PD-L1 si

BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.

Substituted phenyl compound and application thereof

The present invention discloses a substituted phenyl compound and an application thereof, and provides a substituted phenyl compound represented by formula I, or pharmaceutically acceptable salt, a hydrate, a solvate, a metabolite, a stereoisomer, a tautomer or a prodrug thereof. The compound I provided by the invention has the advantages of high activity, high bioavailability, stable drug and oral administration.

UREA COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF

The present invention relates to a urea compound and a preparation method and an application thereof. The structure of the present compound is represented by formula (I), the definition of each variable in the formula being as described in the description. The compound can block interaction between the PD-1/PD-L1 signalling pathways. The compound of the present invention can be used for treating or preventing diseases related to the signalling pathways, such as cancer, autoimmune disease, chronic infectious disease, and other diseases.

SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME

The present invention includes substituted 3,3'-bis(phenoxymethyl)-1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS

The present invention relates to novel substituted dihydropyrazolone derivatives, to their preparation and to their therapeutic use as activators of the transcription factor HIF.

CB1 MODULATOR COMPOUNDS

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.